QbD-based fabrication of transferrin-anchored nanocarriers for targeted drug delivery to macrophages and colon cells for mucosal inflammation healing
Mahira Zeeshan, Qurat Ul Ain, Ahad Sunny, Faisal Raza, Muhammad Mohsin, Salman Khan, Benno Weigmann, Hussain Ali
Abstract
therapeutic efficacy against UC was established through restored morphological and histopathological scores, vascular integrity, antioxidant levels, hematological parameters, pro-inflammatory cytokine/marker levels, and microbial indices. Tofa-P/tfr NCs shut down the elevated STAT-1 and TFR-1 levels, demonstrating the enhanced efficacy of the encapsulated drug. Thus, the QbD-driven approach successfully developed Tofa-P/tfr NCs with good potential to mitigate mucosal inflammation by targeting colon and macrophage surface receptors.
Topics & Concepts
NanocarriersTransferrin receptorChemistryTransferrinInflammationDrug deliveryIn vivoPharmacologyColitisImmunologyMedicineBiologyBiochemistryBiotechnologyOrganic chemistryAdvanced Drug Delivery SystemsMicroscopic ColitisInhalation and Respiratory Drug Delivery